Handelsavisen
prelaunch
Companies Healthcare 217730.KQ
21
217730.KQ KOSDAQ Pharmaceuticals

217730.Kq

$2 715,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
255,4B KRW
P/E
EV / Rev
Div yield
Op margin
-494,4 %
ROE
-15,3 %
Net margin
-293,4 %
Debt / equity
0,14
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and related services.

Business. The company operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and related services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-15,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 217730.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 217730.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and related services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.14, indicating a conservative leverage position. However, the company's liquidity is assessed as medium, with a current ratio of 5.25, suggesting it has sufficient short-term assets to cover its liabilities. The price-to-book ratio of 4.41 and the price-to-tangible-book ratio of 4.41 indicate that the company's market value is significantly higher than its book value, which may reflect investor expectations of future growth or intangible assets.

    Profitability metrics show a challenging financial position, with a return on equity of -0.1527 and a return on assets of -0.1286, both indicating a negative return to shareholders and asset holders. The company reported a net loss of 10,482,078,490 KRW, and an operating loss of 17,663,742,110 KRW, which is significantly below the industry median for profitability metrics. These figures suggest the company is currently unprofitable and may be investing heavily in R&D or facing operational challenges.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may increase the company's exposure to market-specific risks, such as regulatory changes or economic downturns in its primary operating region.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at -11,675,962,560 KRW, and its free cash flow is also negative at -8,763,745,310 KRW, indicating that it is not generating sufficient cash from operations to fund its activities or growth initiatives. The capital expenditure of -660,835,490 KRW suggests the company is investing in its operations, but the negative value indicates a reduction in capital spending.

    The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity constraints. The company's dilution risk is assessed as low, with no significant dilution potential identified in the available data. The company's valuation adjustments do not indicate any material changes to its financial position.

    Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's financial statements and disclosures do not mention any recent significant events, such as mergers, acquisitions, or major regulatory actions, that would impact its financial position or strategic direction.

    Key takeaways
    • The company has a conservative capital structure with a low debt-to-equity ratio of 0.14.
    • The company is currently unprofitable, with a return on equity of -0.1527 and a return on assets of -0.1286.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company's liquidity is assessed as medium, with a current ratio of 5.25.
    • The company's growth trajectory is uncertain, with negative operating and free cash flows.
    • The company's risk profile is marked by a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2 715,00
    Market cap
    $302.85B
    Enterprise value
    $310.29B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    4.4x
    P / Tangible book
    4.4x
    Tangible book
    $68.65B
    Net cash
    -$7.43B
    Current ratio
    5.2
    Debt / equity
    0.1
    ROA
    -12.9%
    ROE
    -15.3%
    Cash conversion
    111.0%
    CapEx / revenue
    -18.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-494,4 %Bottom quartile
    Net Margin-293,4 %Bottom quartile
    ROE-15,3 %Bottom quartile
    Capex / Rev-18,5 %Bottom quartile
    D/E0,14Above median
    Cash Conv1,11Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 217730.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    217730.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage